Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.
Press releases published on June 16, 2025
SS Innovations Announces Successful Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company’s SSi Mantra 3 Surgical Robotic System
GlobeNewswire
·
June 16, 2025
FORT LAUDERDALE, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and …
Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program
GlobeNewswire
·
June 16, 2025
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, June 16, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an in situ personalized combination immunotherapy platform for solid tumor cancers, today …
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
GlobeNewswire
·
June 16, 2025
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV- …
Empty Capsules Market Set for US$4.2B by 2029 — What Should Pharma and Nutraceutical Leaders Know?
GlobeNewswire
·
June 16, 2025
Delray Beach, FL, June 16, 2025 (GLOBE NEWSWIRE) -- The global empty capsules market is entering a pivotal phase—set to grow from US$3.1 billion in 2024 to US$4.2 billion by 2029, driven by evolving drug delivery technologies, booming nutraceutical demand, …
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
GlobeNewswire
·
June 16, 2025
Inclusion reflects continued growth and momentum in the company’s mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: …
PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25
GlobeNewswire
·
June 16, 2025
DELRAY BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced preliminary fourth quarter and fiscal year 2025 results and filed Form 12b-25, Notification of Late Filing …
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
GlobeNewswire
·
June 16, 2025
MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B …
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
GlobeNewswire
·
June 16, 2025
CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health …
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
GlobeNewswire
·
June 16, 2025
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the U.S. …
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
GlobeNewswire
·
June 16, 2025
GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX …
Osmol Therapeutics E.U. Patent Allowance for Novel Therapy Targeting Chemotherapy-induced Neuropathy
GlobeNewswire
·
June 16, 2025
NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced …
Extendicare Announces June 2025 Dividend of C$0.042 per Share
GlobeNewswire
·
June 16, 2025
MARKHAM, Ontario, June 16, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of June 2025, which is payable on July …
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
GlobeNewswire
·
June 16, 2025
Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that investigators were willing and able to reduce injectable G …
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
GlobeNewswire
·
June 16, 2025
End of Phase 2 Meeting has been Rescheduled for July 29th Meeting to Discuss Upcoming Clinical Development Plan and Protocol Designs Strategic Partnership Discussions Expected to Accelerate Following a Positive FDA Meeting GLEN ALLEN, Va., June 16, 2025 ( …
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
GlobeNewswire
·
June 16, 2025
SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that it will host an in-person and virtual R…
Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
GlobeNewswire
·
June 16, 2025
MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug …
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study
GlobeNewswire
·
June 16, 2025
The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other …
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
GlobeNewswire
·
June 16, 2025
ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), …
Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH
GlobeNewswire
·
June 16, 2025
LungFit PH II’s smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the country GARDEN CITY, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- …
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
GlobeNewswire
·
June 16, 2025
CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webcast at 8 …